Fibrinolytic function after dietary supplementation with ω3 polyunsaturated fatty acids

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 5, 1997, Pages 814-819

  Toft, Ingrid ^a,b   Bønaa, Kaare H ^a   Ingebretsen, Ole C ^b   Nordøy, Arne ^b   Jenssen, Trond ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

fibrinolysis; hypertension; plasminogen activator inhibitor type 1; 3 PUFA

Indexed keywords

BLOOD CLOTTING FACTOR 7; CORN OIL; DOCOSAHEXAENOIC ACID; FIBRINOGEN; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; GLUCOSE METABOLISM; HEMATOLOGICAL PARAMETERS; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NORWAY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0030991505     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.5.814     Document Type: Article

References (15)

1. Juhan Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator and urokinase in normal and pathological conditions. Thromb Res. 1984;33:523-530.
2. Vague P, Juhan Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
3. Mykkanen L, Ronnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
4. Ley CJ, Swan J, Godsland IF, Walton C, Crook D, Stevenson JC. Insulin resistance, lipoproteins, body fat and haemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. J Am Coll Cardiol. 1994;23:377-383.
5. Asplund Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817-825.
6. Juhan Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris: the ECAT Angina Pectoris Study Group. Arterioscler Thromb. 1993;13:1865-1873.
7. Juhan Vague I, Vague P. Hypofibrinolysis and insulin resistance. Diabete Metab. 1991;17:96-100.
8. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
9. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
10. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis. 1991;34:179-192.
11. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 1990;227:273-278.
12. Nordby G, Haaland A, Os I. Evidence of decreased fibrinolytic activity in hypertensive premenopausal women. Scand J Clin Lab Invest. 1992;52:275-281.
13. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia and coronary heart disease. Am Heart J. 1991;121:1283-1288.
14. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-422.
15. Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med. 1989;320:1037-1043.